Research programme: cannabinoid receptor CB1 antagonists - Bristol-Myers Squibb

Drug Profile

Research programme: cannabinoid receptor CB1 antagonists - Bristol-Myers Squibb

Alternative Names: BMS-812204

Latest Information Update: 11 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Pyridazines; Small molecules; Triazoles
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 07 Nov 2013 Discontinued - Preclinical for Obesity in USA (PO)
  • 01 Sep 2011 Preclinical development is ongoing in USA
  • 20 Aug 2009 Pharmacodynamics, pharmacokinetics and adverse events data from Preclinical trials in Obesity presented at the 238th American Chemical Society National Meeting (238th-ACS-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top